Skip to content

Fermented infant formula with prebiotics study.

A randomised, controlled, double-blind, equivalence trial to test growth with and tolerance of new infant formulae in healthy, term infants.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25687
Enrollment
344
Registered
2010-09-17
Start date
2010-09-22
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy term infants.

Interventions

Duration of intervention: 15-19 weeks
1. Intervention groups: Cow's milk-based fermented infant formulae with prebiotics (combination of two pre-existing products which stimulate digestion)
2. Control groups: Cow's milk-based fermented/non-fermented infant formulae with/without prebiotics.

Sponsors

Danone Research - Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy, term (gestational age ¡Ý 37 and ¡Ü 42 weeks) infants; 2. Birth weight between 2,5-4,5 kg. These data is derived from WHO growth curves to look at group between 10th and 90th percentile; 3. Age ¡Ü 28 days; 4. Parents' or guardian's aged >18 years, written informed consent.

Exclusion criteria

Exclusion criteria: 1. Breastfeeding; 2. Congenital condition and/or previous or current illness that could interfere with study; 3. Known or increased risk of cow¡¯s milk allergy, soy allergy and/or lactose intolerance; 4. Having a mother suffering from diabetes during pregnancy; 5. Participation in another clinical trial; 6. Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.

Design outcomes

Primary

MeasureTime frame
Weight gain in grams per day from study entry until 17 weeks of age.

Secondary

MeasureTime frame
Anthropometrics other than weight gain, gastrointestinal tolerance, crying, sleeping, stool characteristics, faecal parameters, safety, use of medication and nutritional supplements.

Contacts

Public ContactManon Gadellaa

PO Box 7005

manon.gadellaa@danone.com+31 (0)317 467942

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)